In this session, Opinium reveals the highly anticipated results of NSF’s 2025 European Pharma & Biotech Benchmarking Study—offering one of the most comprehensive snapshots to date of the sector’s quality, compliance, and operational health.
The presentation explores insights from 100 quality and regulatory leaders across Europe, uncovering how organisations are managing risk, maturing their quality systems, investing in people and technology, and adapting to regulatory change.
Key themes from the research include:
- Quality System Maturity Gaps - Only half of companies report advanced or risk-based quality systems, leaving a significant proportion exposed to compliance vulnerabilities.
- Data Integrity Depends on Culture - While system integration and legacy platforms remain challenges, the most effective long-term solutions are quality culture initiatives, including training and governance.
- Supply Chain Weaknesses - Raw material sourcing, authentication, data transparency, and outsourcing oversight present ongoing risks.
- Inspection Readiness - Continuous compliance is the most common approach, yet the industry still lacks a unified standard for maintaining readiness.
- Investment in People and Technology - Organisations are split evenly between prioritising tech or human resource investment, but the drivers for both reveal a dual dependency: operational agility, compliance readiness, and advanced analytics.
- AI as a Transformation Catalyst - AI and machine learning top the list of technologies expected to revolutionise quality management, though validation, ROI justification, and legacy system compatibility remain barriers.
- Future Skills Needs - Regulatory intelligence, advanced risk management, and data analytics emerge as the most essential skills for the next five years.
- Regulatory Pressure - The EU Annex 1 revision is viewed as the most significant compliance challenge, reinforcing the need for enhanced training, cross-functional task forces, and—where required—complete QMS redesigns.
If you want a clear, research-backed view of where European pharma and biotech organisations stand—and where they must evolve—this presentation delivers vital insights.
Download or explore the full report here
